To amend titles XI and XVIII of the Social Security Act to provide greater transparency for discounts provided by manufacturers, to include real-time benefit information as part of a prescription drug plan's electronic prescription program under the Medicare program, and for other purposes.
The bill’s titles are written by its sponsor.
Sponsor and status
Passed House (Senate next) on Oct 28, 2019
This bill passed in the House on October 28, 2019 and goes to the Senate next for consideration.
Position statements
What legislators are saying
“U.S. House Passes Arrington-Spanberger-Boyle Bill to Increase Negotiation Transparency, Lower Costs of Prescription Drugs”
—
Rep. Jodey Arrington [R-TX19]
(Co-sponsor)
on Oct 29, 2019
“My Votes – Week of October 28”
—
Rep. Cathy McMorris Rodgers [R-WA5]
on Nov 1, 2019
“the daily leader: monday, october 28, 2019”
—
Rep. Steny Hoyer [D-MD5]
on Oct 27, 2019
History
H.R. 2115 is a bill in the United States Congress.
A bill must be passed by both the House and Senate in identical form and then be signed by the President to become law.
How to cite this information.
We recommend the following MLA-formatted citation when using the information you see here in academic work:
“H.R. 2115 — 116th Congress: Public Disclosure of Drug Discounts and Real-Time Beneficiary Drug Cost Act.” www.GovTrack.us. 2019. January 27, 2020 <https://www.govtrack.us/congress/bills/116/hr2115>
- show another citation format:
- APA
- Blue Book
- Wikipedia Template
Where is this information from?
GovTrack automatically collects legislative information from a variety of governmental and non-governmental sources. This page is sourced primarily from Congress.gov, the official portal of the United States Congress. Congress.gov is generally updated one day after events occur, and so legislative activity shown here may be one day behind. Data via the congress project.
